CD40LG and Crohn disease: Genetic and antibody-mediated inhibition of CD40 or CD40L successfully reduced disease burden in experimental models of atherosclerosis, Crohn’s disease, psoriasis, rheumatoid arthritis (RA), and experimental autoimmune encephalomyelitis (EAE) (14).